FDA Approves 1st Generics of Vyvanse Amid ADHD Medicine Shortage

A sign for the Food and Drug Administration (FDA) outside of the headquarters in White Oak, Md., on July 20, 2020. Sarah Silbiger/Getty Images

The U.S. Food and Drug Administration (FDA) has approved the first generics of Vyvanse for attention deficit hyperactivity disorder (ADHD) to address the ongoing shortage of ADHD medicine in the United States.

The FDA said on Aug. 28 that it had approved several generics of Takeda Pharmaceutical’s drug Vyvanse for people aged 6 years and older with ADHD and for adults with moderate and severe binge-eating disorder.